Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GLAUKOS CORPORATION

(GKOS)
  Report
Delayed Nyse  -  04:00:01 2023-01-30 pm EST
48.28 USD   +0.50%
01/11Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable Safety and Tolerability
AQ
01/10Transcript : Glaukos Corporation Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 05:15 PM
CI
01/10Glaukos Says iDose TR Exchange Trial Shows 'Favorable' Safety, Tolerability; Shares Up After Hours
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société GLAUKOS CORPORATION
01/11Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable S..
AQ
01/10Glaukos : Investor Presentation January 2023
PU
01/10Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/10Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Program..
BU
01/10Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable ..
BU
2022Glaukos Announces Participation in the J.P. Morgan Healthcare Conference 2023
AQ
2022Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
BU
2022Glaukos Corp : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial ..
AQ
2022Glaukos : Investor Presentation November 2022
PU
2022Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Glaukos Announces Participation in the Stephens Annual Investment Conference
BU
2022GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2022Glaukos : Q3 Earnings Snapshot
AQ
2022Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
AQ
2022Glaukos Corporation Announces Third Quarter 2022 Financial Results
BU
2022Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November ..
BU
2022Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Aca..
BU
2022Coupa Software, Glaukos rise; Occidental Petroleum falls
AQ
2022Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR..
BU
2022Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
BU
2022Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreem..
PR
2022Glaukos Announces Participation in the Wells Fargo Healthcare Conference
BU
2022GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2022Glaukos : Q2 Earnings Snapshot
AQ
2022Glaukos : Announces Second Quarter 2022 Financial Results - Form 8-K
PU
2022Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
AQ
2022Glaukos Announces FDA 510(k) Clearance of iStent infinite®
BU
2022Glaukos Corporation Announces Second Quarter 2022 Financial Results
BU
2022Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
BU
2022Glaukos Corp : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2022Glaukos Announces Participation in the William Blair Growth Stock Conference
BU
2022Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
BU
2022GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2022Glaukos : Q1 Earnings Snapshot
AQ
2022Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
AQ
2022Glaukos Corporation Announces First Quarter 2022 Financial Results
BU
2022Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Soc..
BU
2022Glaukos Announces the Release of its 2021 Sustainability Report
BU
2022Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
BU
2022Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Gen..
BU
2022Glaukos : Investor Presentation March 2022
PU
2022Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022GLAUKOS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
2022Glaukos : Q4 Earnings Snapshot
AQ
2022Glaukos : Announces Fourth Quarter and Full Year 2021 Financial Results - Form 8-K
PU
2022Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi..
AQ
2022Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
BU
2022Glaukos : Announces Executive Leadership Changes - Form 8-K
PU
2022Glaukos Corp : Change in Directors or Principal Officers, Regulation FD Disclosure, Financ..
AQ
2022Glaukos Announces Executive Leadership Changes
BU
2022Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results afte..
BU
2022Glaukos : Investor Presentation January 2022
PU
2022Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2022Glaukos' iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Ov..
BU
2022Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
BU
2022Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
BU
2022Glaukos Announces FDA 510(k) Clearance of iPRIME™
BU
2021Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
BU
2021Glaukos : Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Ele..
PU
2021Glaukos Corp : Change in Directors or Principal Officers, Regulation FD Disclosure, Financ..
AQ
2021Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and El..
BU
2021Glaukos : Investor Presentation November 2021
PU
2021Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
2021Glaukos Announces Participation in Upcoming Investor Conferences
BU
2021Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Aca..
BU
2021GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results o..
AQ
2021Glaukos : Q3 Earnings Snapshot
AQ
2021Glaukos Corporation Announces Third Quarter 2021 Financial Results - Form 8-K
PU
2021GAAP to Non-GAAP Reconciliation Tables – Q3 2021
PU
2021Glaukos Corporation Announces Third Quarter 2021 Financial Results
BU
2021Regulation FD Disclosure - Form 8-K
PU
2021Glaukos Corp : Regulation FD Disclosure (form 8-K)
AQ
2021Glaukos : Investor Presentation August 2021
PU
1  2  3  4  5Next
Upcoming event on GLAUKOS CORPORATION